Compare Bristol-Myers Squibb Co (BMY) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Garmin Ltd. — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Garmin Ltd. trades at $308 (market cap $59.72B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.2× Garmin Ltd.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | GRMN | |
|---|---|---|
Market Cap | $129.94B | $59.72B |
Sector | Health | Technology |
52-Week High | $65.89 | $313.16 |
52-Week Low | $42.60 | $187.10 |
Enterprise Value | $163.92B | $57.23B |
Dividend Yield | 3.96% | 1.36% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
